4Zhu H, Napravnik S, Eron JJ, et al. Decreasing excess mortality of HIV-infected patients initiating antiretroviral therapy: compari- son with mortality in general population in China, 2003-2009 [ J]. .1 Acquir Immune Defic Syndr, 2013,63(5 ) :e150-157.
5Granich R, Crowley S, Vitoria M, et al. Highly active antiretrovi- ral treatment as prevention of H1V transmission: review of scientif- ic evidence and update [J]. Curr Opin HIV AIDS, 2010,5(4) : 298 -304.
8Di Giambenedetto S, Torti C, Prosperi M, et al. Effectiveness of antiretroviral regimens containing abacavir with tenofovir in treat- ment-experienced patients: predictors of virological response and drug resistance evolution in a multi-cohort study [ J ]. Infection, 2009,37(5 ) : 438-444.
9Bannister WP, Ruiz L, Cozzi-Lepri A, et al. Comparison of geno- typic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA [ J]. AIDS, 2008, 22 (3) :367-376.
10Carlson JM, Brumme ZL. HIV evolution in response to HLA-re- stricted CTL selection pressures: a population-based perspective [ J]. Microbes Infect, 2008,10(5 ) : 455-461.
